{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:29:27Z","timestamp":1790861367304,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12072-019-09933-8","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T01:38:45Z","timestamp":1550021925000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-2614","authenticated-orcid":false,"given":"Amr Shaaban","family":"Hanafy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Bassiony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Abd Alkhalik","family":"Basha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"6","key":"9933_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/cld.519","volume":"6","author":"P Kwo","year":"2015","unstructured":"Kwo P, Agrawal S. Treating hepatitis C virus in patients with decompensated cirrhosis: why is it so difficult and does a sustained response rate rescue the patient from liver transplantation? Clin Liver Dis. 2015;6(6):133\u20135.","journal-title":"Clin Liver Dis"},{"key":"9933_CR2","first-page":"111","volume":"58","author":"DM Babusis","year":"2013","unstructured":"Babusis DM, Curry MP, Denning J, Park Y, Murakami E, Afdhal N, et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24\u00a0weeks sofosbuvir (GS-7977) with ribavirin treatment. Hepatology. 2013;58:111.","journal-title":"Hepatology"},{"key":"9933_CR3","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","volume":"13","author":"S Lens","year":"2015","unstructured":"Lens S, Rinc\u00f3n D, Garc\u00eda-Retortillo M, Albillos A, Calleja JL, Ba\u00f1ares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13:1846\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"9933_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/jvh.12465","volume":"22","author":"MA Burchill","year":"2015","unstructured":"Burchill MA, Golden-Mason L, Wind-Rotolo M, Rosen HR. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J Viral Hepat. 2015;22(12):983\u201391.","journal-title":"J Viral Hepat"},{"key":"9933_CR5","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer Van der","year":"2012","unstructured":"Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"issue":"4","key":"9933_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4292\/wjgpt.v6.i4.114","volume":"6","author":"S Ohkoshi","year":"2015","unstructured":"Ohkoshi S, Hirono H, Yamagiwa S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther. 2015;6(4):114\u20139.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"1","key":"9933_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2003.50016","volume":"124","author":"R Wiesner","year":"2003","unstructured":"Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91\u20136.","journal-title":"Gastroenterology"},{"issue":"4","key":"9933_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1128\/JCM.01982-06","volume":"45","author":"F Bouchardeau","year":"2007","unstructured":"Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefr\u00e8re J, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol. 2007;45(4):1140\u20135.","journal-title":"J Clin Microbiol"},{"key":"9933_CR9","first-page":"500","volume-title":"Ultrasound: the essential physics of medical imaging","year":"2012","unstructured":"Bushberg JT, Seitbert JA, Leidholt JE, Boone JM, editors. Ultrasound: the essential physics of medical imaging. 3rd ed. Philadelphia: Wolters Kluwer\/Lippincott Williams & Wilkins; 2012. p. 500\u201375.","edition":"3"},{"issue":"2","key":"9933_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0168-8278(86)80074-5","volume":"2","author":"NW Leung","year":"1986","unstructured":"Leung NW, Farrant P, Peters TJ. Liver volume measurement by ultrasonography in normal subjects and alcoholic patients. J Hepatol. 1986;2(2):157\u201364.","journal-title":"J Hepatol"},{"issue":"3","key":"9933_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1053\/jhep.2002.31250","volume":"35","author":"P Ferenci","year":"2002","unstructured":"Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy\u2014definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716\u201321.","journal-title":"Hepatology"},{"key":"9933_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"9933_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Choijkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"9933_CR14","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/S0168-8278(15)30014-3","volume":"62","author":"R Reddy","year":"2015","unstructured":"Reddy R, Lim JK, Kuo A, Di Bisceglie AM, Vargas HM, Galati JS, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. J Hepatol. 2015;62:S193.","journal-title":"J Hepatol"},{"issue":"3","key":"9933_CR15","first-page":"282","volume":"29","author":"S Manolakopoulos","year":"2016","unstructured":"Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol. 2016;29(3):282\u201396.","journal-title":"Ann Gastroenterol"},{"key":"9933_CR16","first-page":"320A","volume":"60","author":"SL Flamm","year":"2014","unstructured":"Flamm SL, Everson GT, Charlton MR, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology (Baltimore, MD). 2014;60:320A.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9933_CR17","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30003-9","volume":"62","author":"M Manns","year":"2015","unstructured":"Manns M, Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, et al. ledipasvir\/sofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial. J Hepatol. 2015;62:S187\u20138.","journal-title":"J Hepatol"},{"key":"9933_CR18","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/S0168-8278(15)30154-9","volume":"62","author":"F Poordad","year":"2015","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. J Hepatol. 2015;62:S261.","journal-title":"J Hepatol"},{"issue":"10","key":"9933_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jvh.12706","volume":"24","author":"N Afdhal","year":"2017","unstructured":"Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24(10):823\u201331.","journal-title":"J Viral Hepat."},{"key":"9933_CR20","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.1016\/S0168-8278(15)30009-X","volume":"62","author":"G Foster","year":"2015","unstructured":"Foster G, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12\u00a0weeks sofosbuvir and NS5A inhibitors with\/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol. 2015;62:S190\u20131.","journal-title":"J Hepatol"},{"issue":"9","key":"9933_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/apt.14017","volume":"45","author":"M Guarino","year":"2017","unstructured":"Guarino M, Morisco F, Valvano MR, Ippolito AM, Librandi M, Andriulli N, et al. Systematic review: interferon-free regimens for patients with HCV-related child C cirrhosis. Aliment Pharmacol Ther. 2017;45(9):1193\u2013200.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-019-09933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:36:11Z","timestamp":1581536171000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-019-09933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["9933"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09933-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Amr Shaaban Hanafy, Mohamed A. Bassiony and Mohammad Abd Alkhalik Basha declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Zagazig university institutional research committee at the 3rd of May 2015. Written, informed consent was obtained from each patient included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution\u2019s human research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}